Facebook
Twitter
LinkedIn
ForwardNCCN 2024 Pharmacy Updates: A Webinar Series
The rapid integration of new therapeutic agents into treatment for various types of cancer can be challenging for clinicians. Cancer treatment is constantly evolving, and it is crucial for health care professionals to stay up to date with the latest developments in the field. Pharmacists are critical to educating the interprofessional oncology care team about the actions and potential adverse events associated with new and existing therapeutic options. Pharmacists also have an important role in patient safety, education, and quality of care, as well as subsequent monitoring and management of treatment-related toxicities.
This program will provide up-to-date knowledge and skills related to the management of cancer and highlight the importance of interprofessional care and collaboration to ensure the best possible outcomes for patients with cancer.
Target Audience
This program is designed to meet the educational needs of pharmacists, physicians, nurses, nurse practitioners, physician associates/assistants and other health care professionals who manage patients with cancer.
Learning Objectives
The goal of this project is to ensure that pharmacists, physicians, nurses, nurse practitioners, physician associates/assistants, and other members of the interprofessional oncology care team who manage patients with cancer have the knowledge and skills necessary to:
- Apply the current standards of oncology care and NCCN Clinical Practice Guidelines in Oncology to optimize the management of patients with various cancer types.
- Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with cancer.
- Communicate the importance of an interprofessional approach and improve the collaborative performance of the oncology care team in the management of patients with cancer.
Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer
Tuesday, October 29, 2024 • 1:00 – 2:00 PM EDT
Amy Ly Indorf, PharmD, BCOP, Fred Hutchinson Cancer Center
Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer
Wednesday, November 6, 2024 • 2:00 – 3:00 PM EST
Melvin J. Rivera, PharmD, BCOP, The University of Texas MD Anderson Cancer Center
Maintenance Strategies in the Management of Acute Myeloid Leukemia
Wednesday, November 20, 2024 • 2:00 – 3:00 PM EST
Caitlin Rausch, PharmD, BCOP, The University of Texas MD Anderson Cancer Center
Advances in Neoadjuvant Treatment Options in Locally Advanced and Metastatic Rectal Cancer with Deficient Mismatch Repair
Thursday, December 19, 2024 • 12:00 – 1:00 PM EST
Elizabeth Dow-Hillgartner, PharmD, BCOP, University of Wisconsin Carbone Cancer Center
ALL WEBINAR TIMES ARE POSTED AS EASTERN DAYLIGHT TIME (EDT) (UTC/GMT -4:00) OR EASTERN STANDARD TIME (EST) (UTC/GMT -5:00).
Access to participate in selected sessions is through Zoom on the day of each scheduled program.
The most recent recorded webcasts from this series are listed below. Recordings from the previous NCCN Pharmacy Updates series can be found here.
- The Growing Impact of Pharmacogenomics Across the Oncology Landscape (presented on March 18, 2024, by Cyrine Haider, PharmD, BCPS, BCOP, FASHP, St. Jude Children's Research Hospital/The University of Tennessee Health Science Center)
- Oncology Stewardship: Best Practices for Pharmacists in Optimizing Patient Safety and Quality of Care (presented on April 30, 2024, by Christine Hong, PharmD, BCOP, UT Southwestern Simmons Comprehensive Cancer Center)
- Updates in Ovarian Cancer - Putting Together the PARP Puzzle and Understanding a New Therapeutic Target (presented on May 30, 2024, by Farah Raheem, PharmD, BCOP, Mayo Clinic Comprehensive Cancer Center)
- Management of Immunotherapy-Associated Oral Toxicities (presented on June 10, 2024, by Jordan McPherson, PharmD, MS, BCOP, Huntsman Cancer Institute at the University of Utah)
- Hematopoietic Cell Transplantation - An Overview of Hematopoietic Cell Mobilization (presented on July 29, 2024, by Bradley Figgins, PharmD, BCOP, The University of Texas MD Anderson Cancer Center)
- Navigating the Challenging Treatment Landscape for HIV-Associated, Non-AIDS Defining Cancers (presented on August 6, 2024, by Alisha Soares, PharmD, BCOP, and Shannon Balcombe, PharmD, BCPS, AAHIVP, UC San Diego Health)
- What Grade Are You In? The Role of Targeted Therapy in Pediatric Diffuse High-Grade Gliomas (presented on August 30, 2024, by Shirley Qiong Yan, PharmD, BCOP, Memorial Sloan Kettering Cancer Center)
- Updates in the Treatment of Kidney Cancer (presented on September 27, 2024, by Megan Hinkley, PharmD, MBA, BCOP, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute)
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Full disclosure of faculty relationships will be made prior to the activity.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates each live activity in this series for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates each educational activity in this series for a maximum of 1.0 contact hour.
Pharmacists
NCCN designates each application-based continuing education activity in this series for 1.0 contact hour (0.10 CEUs) of continuing education credit.
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. Each activity in this series is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Price
NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.
To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing